Clinical Trial Update: Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating temozolomide with pazopanib in advanced, unresectable pancreatic neuroendocrine tumors; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Islet Cell Carcinoma
• Pancreatic Alpha Cell Carcinoma
• Pancreatic Beta Islet Cell Carcinoma
• Pancreatic Delta Cell Carcinoma
• Pancreatic G-cell Carcinoma
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Pazopanib hydrochloride (pazopanib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Northwestern University | Conditions: Pancreatic Alpha Cell Carcinoma, Pancreatic Beta Islet Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-06-17